Cardiovascular Considerations in Caring for Pregnant Patients

Authors, Journal, Affiliations, Type, DOI

• Authors: Laxmi S. Mehta (Chair), Carole A. Warnes (Vice Chair), Elisa Bradley, Tina Burton, Katherine Economy, Roxana Mehran, Basmah Safdar, Garima Sharma, Malissa Wood, Anne Marie Valente, Annabelle Santos Volgman; on behalf of multiple AHA Councils
• Journal: Circulation. 2020;141:e884–e903
• Affiliations: Multiple academic medical centers across the US
• Type: AHA Scientific Statement
• DOI: 10.1161/CIR.0000000000000772

Overview

This AHA Scientific Statement provides a comprehensive overview of cardiovascular disease (CVD) management during pregnancy, establishing cardio-obstetrics as a multidisciplinary field requiring team-based care from antepartum through 1 year postpartum. CVD is the leading cause of pregnancy-related mortality in the US, rising from 7.2 to 17.2 deaths per 100,000 live births from 1987–2015. The statement covers HDP, ischemic heart disease, cardiomyopathies (including PPCM), arrhythmias, valvular disease, aortic disease, VTE/PE, and cerebrovascular disease in pregnancy. Marked racial and ethnic disparities in pregnancy-related mortality are documented (Black 42.8, AIAN 32.5, Asian/PI 14.2, White 13.0, Hispanic 11.4 per 100,000 live births).

Keywords

Cardiovascular disease, maternal mortality, obstetrics, pregnancy, cardio-obstetrics, peripartum cardiomyopathy, anticoagulation, arrhythmia, valvular heart disease

Key Takeaways

Cardio-Obstetrics Team and Prepregnancy Counseling

• The cardio-obstetrics team (also "pregnancy heart team") includes obstetricians, cardiologists, anesthesiologists, maternal-fetal medicine specialists, geneticists, neurologists, nurses, and pharmacists
• Provides comprehensive care: antepartum + peripartum + postpartum + up to 1 year postpartum
• Modified WHO classification is the only prospectively validated method for maternal CV risk estimation in women with CVD contemplating pregnancy
• Prohibitive/highest-risk conditions: pulmonary arterial hypertension, severe ventricular dysfunction, severe left-sided heart obstruction, significant aortic dilatation with underlying connective tissue disease — women with these conditions are often advised to avoid pregnancy
• Preconception counseling: medication review (ACEi/ARBs are teratogenic → replace before pregnancy), folic acid supplementation, shared decision-making

Physiological Changes During Pregnancy

• Predictable hemodynamic changes: ↑plasma volume, ↑cardiac output, ↓systemic vascular resistance; renin-angiotensin-aldosterone system activation
• Significant fluid shifts at delivery → labile peripartum BP (often rises before delivery, falls within a week)

Hypertensive Disorders in Pregnancy

• HDP occur in 912 per 10,000 delivery hospitalizations; 4-category ACOG classification (preeclampsia/eclampsia, gestational HT, chronic HT, superimposed preeclampsia)
• Severe HT (≥160/110 mmHg confirmed for 15 minutes): treat within 30–60 minutes (IV labetalol, IV hydralazine, or oral nifedipine); IV nitroglycerin preferred when preeclampsia + pulmonary edema
• fullPIERS model: predicts adverse maternal outcomes in admitted preeclampsia patients; variables — gestational age, chest pain/dyspnea, O2 saturation, platelet count, creatinine, AST; BP did not independently predict adverse outcomes in multivariate model
• Postpartum HDP: antihypertensive target SBP <150 mmHg, DBP <100 mmHg for first weeks; early ambulatory visits (1–2 weeks after delivery) essential

Hypercholesterolemia in Pregnancy

• Lipids peak at delivery; do not exceed 250 mg/dL in normal pregnancy
• Statins are contraindicated during pregnancy; bile acid sequestrants are the treatment option for familial hypercholesterolemia; LDL apheresis for severe cases
• Triglycerides >500 mg/dL: risk for pancreatitis; omega-3 fatty acids ± fibrate in second trimester

Ischemic Heart Disease in Pregnancy

• MI risk 3–4× higher in pregnancy; incidence 2.8–8.1 per 100,000 deliveries; mortality 4.5–7.3%
• Atherosclerosis accounts for <50% of cases; SCAD (spontaneous coronary artery dissection) and MINOCA are prevalent causes
• Highest-risk periods: third trimester and postpartum
• Atherosclerotic STEMI: PCI recommended (fetal radiation shielding); thrombolysis rarely used (maternal hemorrhage risk)
• SCAD: conservative management preferred; PCI only for left main dissection, hemodynamic instability, recurrent chest pain, or ongoing ischemia
• Post-PCI: low-dose aspirin safe throughout pregnancy; clopidogrel with caution for shortest duration

Cardiomyopathies in Pregnancy

• PPCM definition: new-onset cardiomyopathy with EF <45%, near end of pregnancy or postpartum, without prior heart disease and no reversible cause
• IPAC study (n=100): LV function recovery almost exclusively in first 6 months postpartum; major cardiovascular events (heart transplantation, LVAD, death) occurred almost exclusively in women with EF <30%
• HF management: diuretics (volume), nitrates/hydralazine (afterload), β-blockers/digoxin (rhythm), anticoagulation if necessary
• Bromocriptine: suppresses prolactin; adjunctive treatment per ESC 2018 guidelines; may be considered for PPCM
• Contraception must be discussed before discharge; future pregnancy risk (recurrent PPCM) must be counseled
• HCM: up to 23% develop HF or arrhythmia-related complications in pregnancy (predominantly third trimester/postpartum); diuretics used cautiously

Arrhythmias in Pregnancy

• Rising pregnancy-related arrhythmia hospitalizations; Black pregnant women have higher arrhythmia frequency
• SVT: adenosine IV if vagal maneuvers fail; Wolff-Parkinson-White: IV procainamide for wide-complex tachycardia
• AF: rate control with digoxin, β-blockers, or CCBs; amiodarone should be avoided; cardioversion is safe
• Congenital LQTS: β-blockade throughout pregnancy; significantly increased malignant tachyarrhythmia risk postpartum
• VT (hemodynamically stable): IV procainamide and lidocaine considered safe; direct cardioversion if unstable
• Catheter ablation can be used if medications fail; minimize radiation exposure

Valvular Heart Disease in Pregnancy

• Regurgitant lesions: generally well tolerated (low afterload from placental circulation); watch for postpartum pulmonary edema when SVR rises acutely
• Left-sided stenotic lesions: highest risk (mitral stenosis, aortic stenosis); symptoms may emerge due to increased volume load
• Mitral stenosis: β-1-selective β-blockers + activity restriction first-line; percutaneous mitral commissurotomy if refractory (ideally after 20 weeks)
• Mechanical prosthetic heart valves: warfarin recommended if dose ≤5 mg/d; if >5 mg/d or patient preference — dose-adjusted LMWH (anti-Xa target 0.8–1.2 U/mL); DOACs should be avoided
• Epidural anesthesia contraindicated in fully anticoagulated patients; hold IV UFH 4–6h, LMWH 24h before epidural; Cesarean section if fully anticoagulated with VKA at time of labor

Anticoagulation in Pregnancy (Table 1)

• UFH: no teratogenicity, does not cross placenta; indicated for acute PE and large DVT or when delivery imminent
• LMWH: preferred over UFH in stable patients; enoxaparin 1 mg/kg subcutaneous every 12h; anti-Xa target 0.6–1.0 U/mL (or 0.8–1.2 U/mL for mechanical valves)
• Warfarin: dose-dependent teratogenicity; avoid in first trimester; acceptable after first trimester in AF/flutter (second-line) and mechanical valves; target INR 2.0–3.0
• DOACs (dabigatran, rivaroxaban, apixaban, edoxaban): avoid in pregnancy (insufficient data; cross placenta)
• Thrombolysis (alteplase): for massive PE or limb-threatening DVT; relative contraindication in pregnancy

Aortic Disease in Pregnancy

• Aortopathy carries WHO risk category III–IV; heritable fibrillinopathies, BAV-associated aortopathy, Turner syndrome are major causes
• Echocardiographic monitoring every 12 weeks (low risk) or monthly (high risk); 6-month post-delivery assessment
• β-blockers for strict BP control
• Stanford type A dissection: surgical emergency; type B: conservative management with strict BP control

Deep Venous Thrombosis and Pulmonary Embolism

• VTE 4–5× more common in pregnancy; absolute risk: 0.3% PE, 1.2% DVT; 70% occur postpartum
• DVT: often proximal (iliac/iliofemoral) and left-sided in pregnancy; serial ultrasonography or MRI pelvis if negative initial US
• PE diagnosis: D-dimer specificity low in pregnancy (rises physiologically each trimester); V/Q scan or CTA depending on availability; no consensus on D-dimer thresholds by gestational week
• LMWH preferred over UFH in stable patients

Cerebrovascular Disease in Pregnancy

• Combined ischemic + hemorrhagic stroke: 30 per 100,000 pregnancies; highest risk in third trimester and first 6 weeks postpartum
• Arterial ischemic stroke: 12.2 per 100,000; risk factors include HDP, sickle cell disease, SLE, migraines
• ICH: 12.2 per 100,000; risk factors include age >35, Black race, preeclampsia/eclampsia
• CVT: 9.1 per 100,000; predominantly in puerperium; anticoagulant choice guided by stage of pregnancy and breastfeeding
• RCVS: thunderclap headache (peak intensity ≤1 minute); treatment — calcium channel blockade (nifedipine) and/or magnesium sulfate
• PRES: secondary to dysfunctional cerebral autoregulation; treatment — hypertension management
• RCVS and PRES can co-occur and manifest with convexity subarachnoid hemorrhage
• Thrombolysis in AIS: relative contraindication in pregnancy unless disabling stroke; retrospective data suggest safety

Timing and Mode of Delivery

• Vaginal delivery preferred for most women with heart disease in pregnancy
• Cesarean for obstetric indications or if fully anticoagulated with VKA at labor
• ACOG recommends elective induction 39–40 weeks for cardiac disease patients

Postpartum Follow-Up and Contraception

• Adverse pregnancy outcomes (HDP, preterm birth, GDM, SGA) are included in the 2018 multisociety blood cholesterol management guideline as CVD risk-enhancing conditions — fourth-trimester follow-up warranted for all APO patients; aggressive risk factor modification at this visit
• APOs share common placental dysfunction/oxidative stress pathways and predict future CVD (hypertension, ischemic heart disease, stroke)
• Contraception (Table 2): IUD and progestin-only implant/pill generally reasonable across most CVD conditions; combined hormonal contraception (CHC) unreasonable in: DVT/PE history, hypertension with vascular disease, PPCM (even with mild dysfunction), complicated valvular disease, ischemic heart disease

Limitations of the Document

• 2020 statement; does not incorporate post-2020 RCT data (e.g., CHAP trial, updated preeclampsia aspirin data, newer LMWH dosing protocols)
• Most recommendations based on observational data, small case series, and expert consensus — very few RCTs in pregnant cardiovascular populations
• Congenital heart disease and sudden cardiac arrest explicitly excluded (addressed in other AHA statements)
• Lack of specificity for non-US practice contexts (e.g., rheumatic heart disease epidemiology; different resource settings)

Key Concepts Mentioned

• concepts/Cardio-Obstetrics — core framework of this statement; team composition, scope of care
• concepts/Hypertensive-Disorders-of-Pregnancy — HDP classification, BP targets, severe HT management
• concepts/Preeclampsia — fullPIERS model; cerebrovascular complications (RCVS/PRES/ICH/CVT)
• concepts/Adverse-Pregnancy-Outcomes — APOs as 2018 cholesterol guideline CVD risk-enhancing conditions; fourth-trimester follow-up
• concepts/LQTS-Pregnancy-Management — LQTS risk and β-blockade throughout pregnancy
• concepts/MINOCA — SCAD and MINOCA highlighted as prevalent causes of MI in pregnancy alongside atherosclerosis; account for >50% of ischemic events in pregnancy

Key Entities Mentioned

• entities/Peripartum-Cardiomyopathy — definition, IPAC study, bromocriptine, prognosis by EF
• entities/Maternal-Health-Disparities — racial/ethnic maternal mortality ratios (Black 42.8, AIAN 32.5, White 13.0 per 100k)
• entities/Hypertension — antihypertensive management during and after pregnancy

Wiki Pages Updated

• wiki/sources/cv-pregnancy-aha-2020.md (created)
• wiki/concepts/Cardio-Obstetrics.md (created)
• wiki/entities/Peripartum-Cardiomyopathy.md (created)
• wiki/concepts/Preeclampsia.md (updated: fullPIERS model, cerebrovascular complications)
• wiki/concepts/Adverse-Pregnancy-Outcomes.md (updated: fourth-trimester follow-up, 2018 cholesterol guideline CVD risk-enhancing conditions)
• wiki/wikiindex.md (updated)
• wiki/sourceindex.md (updated)
• wiki/log.md (updated)